Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Speculating about the Protocol

<< Previous

Bullboard Posts

Next >>

Comment by longterm56on Aug 13, 2020 8:31pm

143 Views

Post# 31406212

RE:RE:Speculating about the Protocol

While we're speculating .... exactly what are they waiting for? Are they still awaiting approval from the agencies? Waiting on a big pharma to finalize partnering deals? Waiting on analysts to get back from vacation? Waiting for patents to be confirmed? ... just what is it that was expected to happen "mid year" and is now "a couple of months"????

-LT

Bucknelly21 wrote: I think that's a good baseline, I am surprised that no one has asked them anymore about the general nash since that seems to still be on the table. And as far as being quiet till September, we all now it's pretty quiet here all the time lol

<< Previous

Bullboard Posts

Next >>

Canadians having more difficulty saving for retirement, study finds